Supramolecular nanoparticles that target phosphatidylinositol-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy

Ashish A. Kulkarni, Bhaskar Roy, Poornima S. Rao, Gregory A. Wyant, Ayaat Mahmoud, Madhumitha Ramachandran, Poulomi Sengupta, Aaron Goldman, Venkata Ramana Kotamraju, Sudipta Basu, Raghunath A Mashelkar, Erkki Ruoslahti, Daniela M. Dinulescu, Shiladitya Sengupta. Laboratory for Nanomedicine, Division of Biomedical Engineering, Department of Medicine, Brigham and Women’s Hospital, Cambridge, MA, USA; Harvard–MIT Division of Health Sciences and Technology, Cambridge, MA, USA; Indo–US Joint Center for Nanobiotechnology, Cambridge, MA, USA; Department of Pathology, Brigham and Women’s Hospital, Boston, MA; Harvard Medical School, Boston, MA, USA; Cancer Research Center, Sanford-Burnham Medical Research Institute, La Jolla, CA and Center for Nanomedicine and Department of Cell, Molecular and Developmental Biology, Bio II, Rm. #3119 University of California, Santa Barbara Santa Barbara, CA, USA. Indian Institute for Science Education Research (IISER), Pune, India. National Chemical Laboratories, Pune, India. Dana Farber Cancer Institute, Brookline, MA, USA;